You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Colorcon
Dow
Express Scripts
Baxter

Last Updated: July 5, 2020

DrugPatentWatch Database Preview

Patent: 7,833,546

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,833,546
Title:Pharmaceutical dosage form and method for the production thereof
Abstract: The invention relates to a method for producing a pharmaceutical dosage form as tablets, pellets and/or in the form of an active ingredient-containing matrix, whereby the tablets, pellets and/or active ingredient-containing matrix contain a pharmaceutical active ingredient and a copolymer serving as a coating agent and/or binding agent, and optionally contain a core and pharmaceutically common additives. According to the invention, the copolymer, the pharmaceutical active ingredient, the optionally present core and/or the pharmaceutically common additives are processed using known techniques by melting, injection molding, extrusion, wet granulation, casting, dipping, spreading out, spraying on, or pressing to form tablets, pellets and/or an active ingredient-containing matrix. The inventive method is characterized in that a copolymer is used that consists of 20 to 34 wt. % methacrylic acid, 20 to 69 wt. % methylacrylate and 0 to 40 wt. % ethylacrylate and, optionally, of 0 to 10 wt. % of additional vinylically copolymerizable monomers with the provision that the glass transition temperature of the copolymer is no higher than 60.degree. C. according to ISO 11357-2, Item 3.3.3. The invention also relates to the pharmaceutical dosage form produced according to this method, said copolymer and the use thereof.
Inventor(s): Petereit; Hans-Ulrich (Darmstadt, DE), Suefke; Thomas (Erzhausen, DE), Meier; Christian (Darmstadt, DE), Schnabel; Michael (Biebesheim, DE), Blesing; Ingrid (Fuerth/Odenwald, DE), Grimm; Stefan (Wintersheim, DE)
Assignee: Evonik Roehm GmbH (Darmstadt, DE)
Application Number:10/502,648
Patent Claims:see list of patent claims

Details for Patent 7,833,546

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Baxter Hlthcare Corp MYXREDLIN insulin human SOLUTION;INTRAVENOUS 208157 001 2019-06-20   Start Trial Evonik Roehm GmbH (Darmstadt, DE) 2022-02-27 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Evonik Roehm GmbH (Darmstadt, DE) 2022-02-27 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Evonik Roehm GmbH (Darmstadt, DE) 2022-02-27 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Johnson and Johnson
Dow
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.